Achieving Equity in Precision Medicine: Early Detection of Cancer

Needs Statement

Most medical professionals have insufficient knowledge about the role that precision medicine has in clinical practice. Genetic alterations affect all types of cancer and often affect cardiovascular, autoimmune, and neurological diseases. Laboratory tools used in precision medicine are highly sophisticated and include genomics, proteomics, and other high-dimensional assays. The series will provide regular updates on these tools, the ways the tools could improve patient care, and the ethical and legal issues surrounding genetic testing. The series will also examine how testing for genetically influenced diseases can affect personalized management of individuals and their families.

Educational Objectives

At the conclusion of the session, the participants should be able to:

• Discuss the biological and social determinants of cancer disparities.
• Evaluate the potential pitfalls of novel technologies to generate cancer inequities.
• Explore the need for data diversity to understand and eliminate cancer disparities.

Target Audience

Activity Evaluation

Evaluation by questionnaire will address program content, presentation, and possible bias.

Educational Methods

• Lectures

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Approval

June 1, 2023 through June 30, 2025. Original release date: June 1, 2023.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.